R

Relaro Medical Trials | Dallas, TX

Research site
(Unclaimed)
Location
12655 N Central Expressway Suite 230, Dallas, Texas, United States of America
Site insights

Top conditions

Depression (8 trials)

Depressive Disorder (8 trials)

Pervasive Child Development Disorders (6 trials)

Major Depressive Disorder (6 trials)

Autism Spectrum Disorder (6 trials)

Top treatments

Rapastinel
Ecopipam
Iclepertin
Cariprazine
SPN-810
Troriluzole
Pimavanserin
AB-2004
BI 1358894
Seltorexant

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

14 of 29
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

This study will investigate the efficacy, safety, tolerability, and pharmacokinetics of RO7017773 in participants aged 15-45 years who have been diag...

Active, not recruiting
Autism Spectrum Disorder (ASD)
Drug: RO7017773
Drug: Placebo

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Other: Placebo
Drug: Aticaprant

The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depr...

Active, not recruiting
Depressive Disorder, Major
Drug: Placebo
Drug: Seltorexant

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

The purpose of this study is to establish the potential benefits, safety, and tolerability of AB-2004 in participants with irritability associated wi...

Active, not recruiting
Autism Spectrum Disorder (ASD)
Drug: Placebo
Drug: AB-2004

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Enrolling
Schizophrenia
Drug: Placebo
Drug: Iclepertin

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the trea...

Enrolling
Irritability Associated With Autism Spectrum Disorder
Drug: Pimavanserin

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism sp...

Enrolling
Irritability Associated With Autism Spectrum Disorder
Drug: Pimavanserin
Drug: Placebo

Autism spectrum disorder (ASD) consists of deficits in social, communication, and cognitive development, repetitive and stereotypic behaviors. Many A...

Enrolling
Autism Spectrum Disorder
Drug: Placebo
Drug: Cariprazine

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Ubrogepant
Drug: Placebo-Matching Ubrogepant

Trial sponsors

AbbVie logo

AbbVie (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems